ONE:ONE

EQUAL ACCESS

ONE:ONE

EQUAL ACCESS

Hearing loss in children and young working adults is a vast but hidden global health issue. Every time you purchase ACEMg, HHS donates the same to benefit children and young adults.

 

Genetic Hearing Loss (GHL)

Mutations of the GJB2 gene (connexin 26, or Cx26) cause about half of all hearing loss in children. ACEMg has been demonstrated to be beneficial for safely reducing hearing loss due to these genetic mutations. HHS will donate ACEMg clinical medicine for Cx26 RCT trials.

 

Drug Induced Hearing Loss (DIHL)

Aminoglycosides (Ag) are an inexpensive, effective treatment for gram-negative bacterial infection. They have been used for decades throughout the world. The hearing loss side effect is well-known. Many millions of neonates and children, especially children in low and middle income countries (LMIC) are disproportionately affected. The scale of the DIHL problem is unknown; reliable data are unavailable. There is no substitute for these drugs. ACEMg has been demonstrated to treat this side effect safely. HHS donates ACEMg to pediatric clinics prescribing aminoglycoside antibiotics.

Noise Induced Hearing Loss (NIHL)

Ongoing exposure to intense sound and noise causes permanent hearing loss. Industrial noise is intense throughout the world, but is less strictly regulated in LMICs. To overcome challenges of access and affordability, HHS donates ACEMg to LMIC industrial workers.

ACCESS FOR ALL

Hearing loss is unequally distributed. 10% is in high income countries (HIC); 90% in low and middle income countries. Our goal is to solve the problem for everyone with our public benefit mission, vision and values. Our focus is the 1.1 billion people aged 12-35 at risk for hearing loss early in life from personal digital music players and loud music at bars, clubs, music festivals and parties. 

Are you a charity, NGO, or running a government program that could benefit from working with us to deliver hearing preservation to those that need it the most?

We are always looking for partners to collaborate with for our ONE:ONE Equal Access program. Fill in the form below with your details and we will get back to as soon as possible: